3 important developments in heart medicine this week
Last week, cardiovascular professionals from around the world came together to hear about the latest scientific findings in their field.
Here are three highlights from the American College of Cardiology’s annual meeting that we thought you’d be interested in:
Rivaroxaban beats aspirin when it comes to treating VTE
Clinicians now have good-quality evidence to support the use of long-term, reduced-intensity anticoagulation therapy with the direct-acting oral anticoagulant (DOAC) rivaroxaban.
The research shows that such treatment reduces the risk of recurrent VTE